Keloid Market Size to Reach USD 356.3 Million by 2035 - Epidemiology Report by IMARC Group

The report provides a detailed analysis of the current keloid marketed drugs and late-stage pipeline drugs.

BROOKLYN, NY, UNITED STATES, July 4, 2025 /EINPresswire.com/ -- The keloid market size reached a value of USD 242.8 million in 2024. Looking forward, IMARC Group expects the 7MM to reach USD 356.3 million by 2035, exhibiting a growth rate (CAGR) of 3.53% during 2025-2035.

Keloids are unique aberrant scars that arise collagen overproduction in response to skin injury, gradually expanding beyond the original wound. Keloids may develop from burns, surgical incisions, acne, and piercings. They often present as lumpy or ridged formations which can be flesh-colored, red, or pink. Notably, these scars tend to itch and become tender when irritated. Keloid formation is prevalent in individuals younger than thirty years, and among darker skinned populations, including Black, Asian, and Hispanic individuals, often with a familial pattern.

This demographic distribution suggests that keloid formation has a strong genetic predisposition. This insight emphasizes the need for research into ethnic-specific factors for devising more equitable and effective treatments. Apart from aesthetics, the condition poses significant discomfort, especially when mobility is restricted due to keloids forming over joints. This indicates that market drivers are rooted in symptoms beyond physical appearance. Two primary factors contributing to the skin trauma market include the global incidence of skin trauma, as a result of burn cases and traffic accidents. These issues, alongside others, expand the patient population looking for treatment, as well as greatly enhancing the market scope. This establishes a sharp point baseline demand for interventions, offering a reliable infrastructure for expansion. In addition, factors such as increased adoption of cosmetic surgery and greater awareness of the effects of keloid scars on one’s appearance have greatly stimulated demand in the market.

Request to get a PDF Sample Report: https://www.imarcgroup.com/keloid-market/requestsample

The keloid treatment landscape is experiencing change as of 2025, becoming more targeted and innovative. Mainstays include intralesional corticosteroid injections which contribute significantly due to their effectiveness in minimizing scarring and associated inflammation. Advanced laser surgeries are increasingly used to reduce larger keloids and treat associated symptoms, often used together with injections for greater efficacy. Newer approaches such as precision microneedling are being studied to administer anti-fibrotic agents directly into the scar tissue to reduce exposure to the rest of the body and increase local action. There is also a shift focusing on using other drugs with anti-fibrotic properties like pirfenidone and tranilast for the treatment of keloids which seeks to enhance accessibility by fast-tracking development.

The futuristic outlook is focusing more on regenerative medicine and gene therapy approaches to treating keloids, emphasizing a shift from managing symptoms to the aim of prevention and cure. Stem cell therapies including Mesenchymal Stem Cells (MSCs) and their exosomes are being studied for their ability to modulate normal healing and mitigate abnormal collagen accumulation. Gene therapy is an area of active investigation, with attempts made to “silence” genes responsible for keloids to permanently eliminate the problem.

The focus on preventing keloid formation, in particular, illustrates the need to combat persisting issues like high rates of reoccurrence, which can surge to 70-90% after surgery alone. The realization that surgery by itself does not suffice has fueled the focus on holistic approaches in combination therapy, making space for integrated care pathways.

Regardless of all the integration of different therapies and treatment paradigms, accessible care continues to be one of the primary obstacles. The exorbitant price of sophisticated care remains a challenge, especially in emerging economies. This affordability-efficacy nexus calls for agile inventiveness paired with effective innovation around reimbursement systems. In addition, the complex and not entirely understood pathophysiology of keloids carries inherent research and regulatory challenges for novel drug development. Developing large publicly accessible datasets to inform AI and machine learning significantly accelerates the ability to detect critical patterns in keloid pathophysiology and therapeutic interventions. This strategy emphasizes the importance of collaboration in research and data sharing between academic and industry partners.

Scientific innovations, advancements, and a greater understanding of scar biology will further propel growth in the keloid market.

The preferred vision seeks to place value on long-term, tailored, preventative, and possibly curative methods which hope to move the market price from ongoing treatment to enduring, high-impact value interventions.

Buy the full Keloid Market Epidemiology Report with TOC: https://www.imarcgroup.com/checkout?id=7544&method=809

The report also provides a detailed analysis of the current keloid marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Competitive Landscape

The competitive landscape of the keloid market has been studied in the report with the detailed profiles of the key players operating in the market.

Bristol-Myers Squibb
Sandoz
3M Health Care
Teva Pharmaceuticals
UCB
UroGen Pharma
Amneal Biosciences
Allergan
Kissei Pharmaceuticals
Topadur Pharma
Innovo Therapeutics
AiViva BioPharma
Sirnaomics

Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the keloid market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the keloid market
Reimbursement scenario in the market
In-market and pipeline drugs

IMARC Group Offers Other Reports:

Agoraphobia Market https://www.einpresswire.com/article/821443845/agoraphobia-market-epidemiology-report-2025-2035-drug-pipeline-treatment-trends-rising-incidence-prevalence

Autism Spectrum Disorder Market https://www.einpresswire.com/article/822691290/autism-spectrum-disorder-market-size-therapeutics-trends-and-rising-global-prevalence-2025-2035

Spinocerebellar Ataxia Market https://www.einpresswire.com/article/822702931/spinocerebellar-ataxia-market-size-2025-2035-treatment-trends-epidemiology-drug-pipeline

Chronic Kidney Disease Market https://www.einpresswire.com/article/825444075/chronic-kidney-disease-epidemiology-report-2025-2035-drug-pipeline-treatment-market-trends-rising-incidence

Niemann-Pick Disease Type C Market https://www.einpresswire.com/article/825441989/niemann-pick-disease-type-c-market-epidemiology-report-2025-2035-drug-pipeline-treatment-trends-rising-incidence

Inflammatory Bowel Disease Market https://www.einpresswire.com/article/825436399/inflammatory-bowel-disease-market-size-to-reach-usd-20-08-billion-by-2035-report-by-imarc-group

Elena Anderson
IMARC Services Private Limited
+1 631-791-1145
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.